Player FM uygulamasıyla çevrimdışı Player FM !
Apr 19 2024 This Week in Cardiology
Manage episode 413436188 series 2291284
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
Substantial Triglyceride Reduction With Plozasiran
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
332 bölüm
Manage episode 413436188 series 2291284
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
Substantial Triglyceride Reduction With Plozasiran
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
332 bölüm
Tüm bölümler
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.